Strategies for the Management of Ocular Surface Disease in Glaucoma

Authors

  • William Trask MD, BSc
  • Adam Muzychuk, MD, FRCSC

DOI:

https://doi.org/10.58931/cect.2023.2121

Abstract

Ocular surface disease (OSD) is a common ophthalmological concern, with a prevalence in the Canadian population estimated at 25%. Amongst glaucoma patients, up to 60% report symptoms of OSD and up to 78% have clinical signs. Surface symptoms significantly reduce glaucoma-related quality-of-life (QOL), and there is emerging evidence to suggest that treatment of OSD may in fact improve intraocular-pressure (IOP) control and contribute to disease stabilization. The treatment of OSD in glaucoma has been receiving increasing attention, however specific recommendations remain sparse.

Ocular surface disease is known to represent a complex milieu of genetic predisposition, adnexal and periorbital status, environmental factors, systemic diseases, and medications (topical and systemic), amongst other predisposing factors. Effective management of this condition therefore demands that treatment be targeted to the specific clinical context. A 2020 study of Canadian glaucoma specialists found that, although 97% identified optimization of ocular surface disease as important for improving patient QOL, only 22.2% felt this was currently being managed adequately in the subspecialty clinic setting. Moreover, although all participants felt comfortable modifying topical hypotensive regimens to improve surface disease, only 61.1% were confident identifying patients who would benefit from topical steroids, and just 30.5% felt knowledgeable regarding the use and dispensation of autologous serum tears, which are increasingly deployed for treatment-resistant OSD in dry-eye practices. There is, therefore, an unmet need for clarity in the treatment algorithm to optimize OSD in glaucoma patients. Here, we discuss the therapeutic approach to these patients and present a suggested algorithm to guide management.

Author Biographies

William Trask MD, BSc

Dr. William Trask is a fourth-year ophthalmology resident at the University of Calgary. He obtained a Bachelor’s in Honors Neuroscience in 2016 and subsequently completed medical school at the University of Calgary. Dr. Trask’s research interests are broad and varied, ranging from cornea and ocular surface through intraocular/orbital malignancies, surgical glaucoma, and optic nerve. He also has a passion for translating technical innovation into the clinical space in the form of 3D printing/rapid prototyping and developing smartphone applications to aid examination and communication in ophthalmology. With a long-seated interest in medical education, he maintains an active role in admissions and instruction at the undergraduate medical education level and has been an invited lecturer to the local medical school. He has been extensively awarded for his clinical and academic achievements over the course of his training and serves as a journal and conference reviewer.

Adam Muzychuk, MD, FRCSC

Dr. Adam Muzychuk is an Assistant Professor of Surgery at the University of Calgary. He obtained his Medical Degree followed by residency training in Ophthalmology at the University of Calgary. Following residency, he completed fellowship training in anterior segment surgery at Université de Montréal. Dr. Muzychuk is the Scientific Meeting Chair for the Eye Physicians and Surgeons of Alberta (EPSAA), and has published in the areas of cornea, glaucoma, and retina. Currently, Dr. Muzychuk is involved in clinical trials on emerging technologies in cataract surgery. He has received more than ten academic awards including Best Paper of the Session at the ASCRS Annual Meeting, Best Glaucoma Paper from the Canadian Glaucoma Society, and the Master Teacher Award in the University of Calgary Section of Ophthalmology. Dr. Muzychuk practices in Calgary and remains active in undergraduate and postgraduate medical education at the University of Calgary.

References

Doughty MJ, Fonn D, Richter D, et al. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optometry Vision Sci. 1997;74:624-31. DOI: https://doi.org/10.1097/00006324-199708000-00023

Ghosh S, O’Hare F, Lamoureux E, et al. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40:675-81. DOI: https://doi.org/10.1111/j.1442-9071.2012.02781.x

Batra R, Tailor R, Mohamed S. Ocular Surface Disease Exacerbated Glaucoma: Optimizing the Ocular Surface Improves Intraocular Pressure Control. J Glaucoma. 2014;23:56-60. DOI: https://doi.org/10.1097/IJG.0b013e318264cd68

Sherwin JC, Ratnarajan G, Elahi B, et al. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clin Exp Ophthalmol. 2018;46:888-94. DOI: https://doi.org/10.1111/ceo.13311

Muzychuk A, Racine L, Robert M, Birt C, Penner V, Harasymowycz P Crichton A, Ford B, Gooi P, Harissi-Dagher M. Management of Ocular Surface Disease in Glaucoma: A Survey of Canadian Glaucoma Specialists. J Glaucoma. 2020;29:1162-1172. DOI: https://doi.org/10.1097/IJG.0000000000001659

Saade CE, Lari HB, Berezina TL, et al. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study. Can J Ophthalmology. 2015;50:132-6. DOI: https://doi.org/10.1016/j.jcjo.2014.11.006

Amparo F, Schaumberg DA, Dana R. Comparison of Two Questionnaires for Dry Eye Symptom Assessment. Ophthalmology. 2015;122:1498-503. DOI: https://doi.org/10.1016/j.ophtha.2015.02.037

Wang MTM, Xue AL, Craig JP. Comparative evaluation of 5 validated symptom questionnaires as screening instruments for dry eye disease. JAMA Ophthalmol. 2019 Feb 1;137(2):228-229. doi:10.1001/jamaophthalmol.2018.5243 DOI: https://doi.org/10.1001/jamaophthalmol.2018.5243

Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. AMA Arch Ophthalmol. 2000;118:615-21. DOI: https://doi.org/10.1001/archopht.118.5.615

Uchiyama E, Aronowicz J, Butovich I, et al. Increased Evaporative Rates in Laboratory Testing Conditions Simulating Airplane Cabin Relative Humidity: An Important Factor for Dry Eye Syndrome. Eye and Contact Lens. 2007;33:174-176 DOI: https://doi.org/10.1097/01.icl.0000252881.04636.5e

Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research. 2010;29:312-34. DOI: https://doi.org/10.1016/j.preteyeres.2010.03.001

Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730-5. DOI: https://doi.org/10.1097/IJG.0b013e31825af67d

Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019 Apr 13;393(10180):1505-1516. doi:10.1016/S0140-6736(18)32213-X DOI: https://doi.org/10.1016/S0140-6736(18)32213-X

Blondeau P, Rousseau J. Allergic reactions to brimonidine in patients treated for glaucoma. Can J Ophthalmol. 2002;37:21-26. DOI: https://doi.org/10.1016/S0008-4182(02)80094-1

Arita R, Morishige N, Shirakawa R, et al. Effects of eyelid warming devices on tear film parameters in normal subjects and patients with meibomian gland dysfunction. Ocul Surf. 2015 Oct;13(4):321-30. doi:10.1016/j.jtos.2015.04.005 DOI: https://doi.org/10.1016/j.jtos.2015.04.005

Asbell PA, Maguire MG, Pistilli M, Ying GS, Szczotka-Flynn LB, et al; Dry Eye Assessment and Management Study Research Group. n−3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. New Engl J Med. 2018 May 3;378(18):1681-1690. doi:10.1056/NEJMoa1709691 DOI: https://doi.org/10.1056/NEJMoa1709691

Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials. Cornea. 2019 May;38(5):565-573. doi:10.1097/ICO.0000000000001884 DOI: https://doi.org/10.1097/ICO.0000000000001884

Saini M, Dhiman R, Dada T, et al. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015 Jun;29(6):808-14. doi:10.1038/eye.2015.40 DOI: https://doi.org/10.1038/eye.2015.40

Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Brit J Ophthalmol. 2004;88:647-52. DOI: https://doi.org/10.1136/bjo.2003.026211

Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative Nonsteroidal Anti-inflammatory Drug or Steroid and Outcomes after Trabeculectomy: A Randomized Controlled Trial. Ophthalmol. 2010;117:1324-30. DOI: https://doi.org/10.1016/j.ophtha.2009.11.038

Toyos MM, Toyos R. Clinical outcomes of micropulsed transcleral cyclophotocoagulation in moderate to severe glaucoma. J Clin Exp Ophthalmol. 2016;7(6):620-2. DOI: https://doi.org/10.4172/2155-9570.1000620

Ji H, Zhu Y, Zhang Y, et al. Dry Eye Disease in Patients with Functioning Filtering Blebs after Trabeculectomy. PLOS One. 2016 Mar 31;11(3):e0152696. doi:10.1371/journal.pone.0152696 DOI: https://doi.org/10.1371/journal.pone.0152696

Mukhopadhyay S, Thakur S, Dutta J, et al. Effect of mitomycin C-aided trabeculectomy on conjunctival goblet cell density. Nepal J Ophthalmol. 2012 Jan-Jun;4(1):68-72. doi:10.3126/nepjoph.v4i1.5854 DOI: https://doi.org/10.3126/nepjoph.v4i1.5854

Uzunosmanoglu E, Mocan M, Kocabeyoglu S, et al. Meibomian Gland Dysfunction in Patients Receiving Long-Term Glaucoma Medications. Cornea. 2016 Aug;35(8):1112-6. doi:10.1097/ICO.0000000000000838 DOI: https://doi.org/10.1097/ICO.0000000000000838

Martinez-de-la-Casa J, Oribio-Quinto C, Milans-del-Bosch A, et al. Intense pulsed light-based treatment for the improvement of symptoms in glaucoma patients treated with hypotensive eye drops. Eye Vis (Lond). 2022 Apr 1;9(1):12. doi:10.1186/s40662-022-00284-4 DOI: https://doi.org/10.1186/s40662-022-00284-4

Kasetsuwan N, Suwajanakorn D, Tantipat C, et al. The Efficacy Between Conventional Lid Hygiene and Additional Thermal Pulsatile System in Meibomian Gland Dysfunction Patients Treated with Long-Term Anti-Glaucoma Medications in a Randomized Controlled Trial. Clinical Ophthalmol. 2020 Sep 28;14:2891-2902. doi:10.2147/OPTH.S259692 DOI: https://doi.org/10.2147/OPTH.S259692

Downloads

Published

2023-02-01

How to Cite

1.
Trask W, Muzychuk A. Strategies for the Management of Ocular Surface Disease in Glaucoma. Can Eye Care Today [Internet]. 2023 Feb. 1 [cited 2024 Dec. 22];2(1):10–14. Available from: https://canadianeyecaretoday.com/article/view/2-1-2

Issue

Volume 2, Issue 1, February 2023

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.